Case Control Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 6, 2020; 8(5): 874-886
Published online Mar 6, 2020. doi: 10.12998/wjcc.v8.i5.874
Significance of 125I radioactive seed implantation on growth differentiation factor and programmed death receptor-1 during treatment of oral cancer
Gang Xue, Yao Feng, Jia-Bin Li
Gang Xue, Department II of Prosthodontics, The Second Affiliated Hospital of Jiamusi University, Jiamusi 154000, Heilongjiang Province, China
Yao Feng, Department I of Endodontics, The Second Affiliated Hospital of Jiamusi University, Jiamusi 154000, Heilongjiang Province, China
Jia-Bin Li, Department II of Oral and Maxillofacial Surgery, The Second Affiliated Hospital of Jiamusi University, Jiamusi 154000, Heilongjiang Province, China
Author contributions: Xue G designed the research and performed the research; Feng Y analyzed the data; Li JB wrote the paper. Xue G and Feng Y contributed equally to this work.
Supported by Heilongjiang Provincial Health and Family Planning Commission Research Project, No. 2017-413.
Institutional review board statement: This study was reviewed and approved by the Second Affiliated Hospital of Jiamusi University Ethics Committee.
Informed consent statement: All patients in our study provided informed consent.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jia-Bin Li, MSc, Attending doctor, Department II of Oral and Maxillofacial Surgery, The Second Affiliated Hospital of Jiamusi University, No.522, Hongqi Street, Jiamusi 154000, Heilongjiang Province, China. jiping199210@126.com
Received: November 19, 2019
Peer-review started: November 19, 2019
First decision: December 4, 2019
Revised: December 12, 2019
Accepted: January 8, 2020
Article in press: January 8, 2020
Published online: March 6, 2020
Processing time: 107 Days and 21.7 Hours
Abstract
BACKGROUND

Oral cancer (OC) is the most common malignant tumor in the oral cavity, and is mainly seen in middle-aged and elderly men. At present, OC is mainly treated clinically by surgery or combined with radiotherapy and chemotherapy; but recently, more and more studies have shown that the stress trauma caused by surgery and the side effects of radiotherapy and chemotherapy seriously affect the prognosis of patients.

AIM

To determine the significance of 125I radioactive seed implantation on growth differentiation factor 11 (GDF11) and programmed death receptor-1 (PD-1) during treatment of OC.

METHODS

A total of 184 OC patients admitted to The Second Affiliated Hospital of Jiamusi University from May 2015 to May 2017 were selected as the research subjects for prospective analysis. Of these patients, 89 who received 125I radioactive seed implantation therapy were regarded as the research group (RG) and 95 patients who received surgical treatment were regarded as the control group (CG). The clinical efficacy, incidence of adverse reactions and changes in GDF11 and PD-1 before treatment (T0), 2 wk after treatment (T1), 4 wk after treatment (T2) and 6 wk after treatment (T3) were compared between the two groups.

RESULTS

The efficacy and recurrence rate in the RG were better than those in the CG (P < 0.05), while the incidence of adverse reactions and survival rate were not different. There was no difference in GDF11 and PD-1 between the two groups at T0 and T1, but these factors were lower in the RG than in the CG at T2 and T3 (P < 0.05). Using receiver operating characteristic (ROC) curve analysis, GDF11 and PD-1 had good predictive value for efficacy and recurrence (P < 0.001).

CONCLUSION

125I radioactive seed implantation has clinical efficacy and can reduce the recurrence rate in patients with OC. This therapy has marked potential in clinical application. The detection of GDF11 and PD-1 in patients during treatment showed good predictive value for treatment efficacy and recurrence in OC patients, and may be potential targets for future OC treatment.

Keywords: 125I radioactive seeds; Oral cancer; Growth differentiation factor 11; Programmed death receptor-1; Prognosis; Recurrence

Core tip: 125I radioactive seed implantation for oral cancer (OC) shows clinical efficacy and reduces the recurrence rate in patients, thus has marked potential in clinical applications. The detection of growth differentiation factor 11 and programmed death receptor-1 in patients during treatment demonstrated that this therapy has good predictive value for treatment efficacy and recurrence in OC patients, and may be potential targets for future OC treatment.